参考文献/References:
[1] Torre LA,Bray F,Siegel RL,et al.Global cancer statistics,2012[J].CA-A Cancer Journal Clinicians,2015,65(2):87-108.
[2] 叶肖燕.非小细胞肺癌患者表皮生长因子受体基因突变特征及意义[J].中华实用诊断及治疗杂志,2016,30(1):49-51.
Ye XY.Characteristics and significance of epidermal growth factorreceptor gene mutation in non-small cell lung cancer[J].J Chin Practical Diagnosis and Therapy,2016,30(1):49-51.
[3] She J,Yang P,Hong QY,et al.Lung cancer in China challenges and interventions[J].Chest,2013,143(4):1117-1126.
[4] 赵建国,熊建萍.非小细胞肺癌驱动基因研究进展[J].中国肺癌杂志,2015,18(1):42-47.
Zhao JG,Xiong JP.Advances on driver oncogenes of non-small cell lung cancer[J].Chin J Lung Cancer,2015,18(1):42-47.
[5] 黎谢梦丹,罗 凯,吴顺芳,等.华南地区非小细胞肺癌患者肿瘤组织EGFR,ALK和ROS1基因突变分析[J].现代检验医学杂志,2017,32(5):16-18,23.
Lixie MD,Luo K,Wu SF,et al.Mutation analysis of EGFR,ALK and ROS1 in tumor tissues of patients with non-small cell lung cancer in south of China[J].J Mod Lab Med,2017,32(5):16-18,23.
[6] Yamamoto H,Toyooka S,Mitsudomi T.Impact of E-GFR mutation analysis innon-small cell lung cancer[J].Lung Cancer,2018,63(3):315-324.
[7] Shaw AT,Yeap BY,Solomon BJ,et al.Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK generearrangement:a retrospective analysis[J].Lancet Oncol,2011,12(11):1004-1012.
[8] Ou SH,Tan J,Yen Y,et al.ROS1 as a “druggable” receptor tyrosine kinase:lessons learned from inhibiting the ALK pathway[J].Expert Rev AnticancerTher,2012,12(4):447-456.
[9] Sholl L.Molecular diagnostics of lung cancer in the clinic[J].TranslLung Cancer Res,2017,6(5):560-569.
[10] Shao AT,Ou SH,Bang YJ,et al.Crizotinib in ROS1 rearranged non-small cell lung cancer[J].N Engl J Med,2014,371(21):1963-1971.
[11] 中国非小细胞肺癌患者表皮生长因子受体基因突变检测专家组.中国非小细胞肺癌患者表皮生长因子受体基因突变检测专家共识(2016版)[J].中华病理学杂志,2016,45(4):217-220.
Expert Group for Detection of Epidermal Growth Fa-ctor Receptor Gene Mutation in Non-small Cell Lung Cancer Patients in China.Expert consensus on the detection of epidermal growth factor receptor gene mutation in non-small cell lung cancer patients in China(2016 edition)[J].Chin J Pathol,2016,45(4):217-220.
[12] Campbell JD,Alexandrov A,Kim J,et al.Distinct pa-tterns of somaticgenome alterations in lung adenocarcinomas and squamous cell carcinomas[J].Nat Genet,2016,48(6):607-616.
[13] Li SY,Choi YL,Gong ZL,et al.Comprehensive cha-racterization of oncogenic drivers in Asian lung adenocarcinoma[J].J Thorac Oncol,2016,11(12):2129-2140.
[14] 杨长绍,杨延龙,丁晓洁,等.非小细胞肺癌患者肿瘤组织多驱动基因联合检测及其临床意义[J]. 临床与实验病理学杂志,2017,33(11):1183-1187.
Yang CS,Yang YL,Ding XJ,et al.Driver gene mutations among non-small cell lung cancer tissues and its clinical significance[J].J Clin Exp Pathol,2017,33(11):1183-1187.
[15] Doss GP,Rajith B,Chakraborty C,et al.Structural signature of the G719S-T790M double mutation in the EGFR kinase domain and its response to inhibitors[J].Sci Rep,2014,4:5868.
[16] Chiu CH,Yang CT,Shih JY,et al.Epidermal growth factor receptor tyrosine kinase inhibitor treatment response in advanced lung adenocarcinomas with G719X/L861Q/S768I mutations[J].J Thorac Oncol,2015,10(5):793-799.
[17] Barnet MB,O'Toole S,Horvath LG,et al.EGFR-Co-Mutated advanced NSCLC and response to EGFR tyrosine kinase inhibitors[J].J Thorac Oncol,2017,12(3):585-590.
相似文献/References:
[1]张 蕾,任亚女,曾婷婷,等.晚期非小细胞肺癌患者血液实验指标和病理分期等因素对生存时间的影响分析[J].现代检验医学杂志,2016,31(02):83.[doi:10.3969/j.issn.1671-7414.2016.02.025]
ZHANG Lei,REN Ya-n,ZENG Ting-ting,et al.Analysis of Prognosis Related Factors in Patients
with Advanced Non-Small Cell Lung Cancer[J].Journal of Modern Laboratory Medicine,2016,31(06):83.[doi:10.3969/j.issn.1671-7414.2016.02.025]
[2]薛鸿涛,任 敏,李长彬.非小细胞肺癌患者放疗前后血清TSGF和CRP的变化及其临床意义[J].现代检验医学杂志,2016,31(02):136.[doi:10.3969/j.issn.1671-7414.2016.02.041]
XUE Hong-tao,REN Min,LI Chang-bin.Impact and Clinical Significance of Radiotherapy on Serum
TSGF and CRP in Patients with Non Small Cell Lung Cancer[J].Journal of Modern Laboratory Medicine,2016,31(06):136.[doi:10.3969/j.issn.1671-7414.2016.02.041]
[3]王京伟,李 艳,童永清,等.湖北地区非小细胞肺癌EGFR 基因突变及其意义的研究[J].现代检验医学杂志,2016,31(03):7.[doi:10.3969/j.issn.1671-7414.2016.03.003]
WANG Jing-wei,LI Yan,TONG Yong-qing,et al.Detection of Epidermal Growth Factor Receptor(EGFR)
Mutations and the Significance in Patients with Non-small Cell Lung
Cancer(NSCLC)of Hubei Province[J].Journal of Modern Laboratory Medicine,2016,31(06):7.[doi:10.3969/j.issn.1671-7414.2016.03.003]
[4]易甲其,范艳平,周宁加,等.血清PTX-3,CYFRA21-1和TPS在非小细胞肺癌中的变化及临床意义[J].现代检验医学杂志,2015,30(05):58.[doi:10.3969/j.issn.1671-7414.2015.05.018]
YI Jia-qi,FAN Yan-ping,ZHOU Ning-jia,et al.Changes and Clinical Significance of Serum PTX-3,
CYFRA21-1,TPS in Non-Small Cell Lung Cancer[J].Journal of Modern Laboratory Medicine,2015,30(06):58.[doi:10.3969/j.issn.1671-7414.2015.05.018]
[5]钱忠萍,凌 晨,祁松楠,等.围非小细胞肺癌手术期T细胞含量变化的研究[J].现代检验医学杂志,2016,31(05):55.[doi:10.3969/j.issn.1671-7414.2016.05.014]
QIAN Zhong-ping,LING Chen,QI Song-nan,et al.Content Variation of T Cells in Perioperative Patients
with Non-Small Cell Lung Cancer[J].Journal of Modern Laboratory Medicine,2016,31(06):55.[doi:10.3969/j.issn.1671-7414.2016.05.014]
[6]李晓锋,刘 希,张冠军,等.ARMS法检测肺腺癌EGFR基因突变及临床意义[J].现代检验医学杂志,2018,33(02):42.[doi:10.3969/j.issn.1671-7414.2018.02.001]
LI Xiao-feng,LIU XI,ZHANG Guan-jun,et al.Detection of EGFR Gene Mutation
in Lung Adenocarcinoma by ARMS and Its Clinical Significance[J].Journal of Modern Laboratory Medicine,2018,33(06):42.[doi:10.3969/j.issn.1671-7414.2018.02.001]
[7]李小龙,白巧艳,陆婉玲.老年非小细胞肺癌患者低分割放疗对凝血功能的影响[J].现代检验医学杂志,2018,33(05):142.[doi:10.3969/j.issn.1671-7414.2018.05.039]
LI Xiao-long,BAI Qiao-yan,LU Wan-ling.Influence of Hypofractionated High-Dose Radiotherapy on Coagulation Function in Elderly Patients with Non-Small Cell Lung Cancer[J].Journal of Modern Laboratory Medicine,2018,33(06):142.[doi:10.3969/j.issn.1671-7414.2018.05.039]
[8]黄 刚,陈 霏,肇玉博,等.非小细胞肺癌患者血浆miRNA-145和miRNA-221表达与临床特征及术后复发的相关性研究[J].现代检验医学杂志,2019,34(04):40.[doi:10.3969/j.issn.1671-7414.2019.04.010]
HUANG Gang,CHEN Fei,ZHAO Yu-bo,et al.Study on the Correlation between the Expression of MicroRNA145
and MicroRNA221 in Plasma and Clinical Characteristics and
Postoperative Recurrence in Patients with Non-Small Cell Lung Cancer[J].Journal of Modern Laboratory Medicine,2019,34(06):40.[doi:10.3969/j.issn.1671-7414.2019.04.010]
[9]蒋玲丽,黄中强,王雪亮,等.表皮生长因子受体(EGFR)基因突变检测质控品制备及应用[J].现代检验医学杂志,2020,35(02):145.[doi:10.3969/j.issn.1671-7414.2020.02.040]
JIANG Ling-li,HUANG Zhong-qiang,WANG Xue-liang,et al.Development and Application of Quality Control Materials for EpidermalGrowth Factor Receptor (EGFR)Mutation Determination[J].Journal of Modern Laboratory Medicine,2020,35(06):145.[doi:10.3969/j.issn.1671-7414.2020.02.040]
[10]彭 琦a,程少鹏b,陈辅萍a.非小细胞肺癌组织中NSE 的基因表达及与患者临床特征的相关性研究[J].现代检验医学杂志,2020,35(03):36.[doi:10.3969/j.issn.1671-7414.2020.03.008]
PENG Qia,CHENG Shao-pengb,CHEN Fu-pinga.Correlation between NSE Gene Expression and Serum NSE Level in Tumor Tissues
and Clinical Characteristics of Patients with Non-Small Cell Lung Cancer[J].Journal of Modern Laboratory Medicine,2020,35(06):36.[doi:10.3969/j.issn.1671-7414.2020.03.008]
[11]黎谢梦丹,罗 凯,吴顺芳,等.华南地区非小细胞肺癌患者肿瘤组织EGFR,ALK和ROS1基因突变分析[J].现代检验医学杂志,2017,32(05):16.[doi:10.3969/j.issn.1671-7414.2017.05.005]
LIXIE Meng-dan,LUO Kai,WU Shun-fang,et al.Mutation Analysis of EGFR,ALK and ROS1 in Tumor Tissues
of Patients with Non-Small Cell Lung Cancer in South of China[J].Journal of Modern Laboratory Medicine,2017,32(06):16.[doi:10.3969/j.issn.1671-7414.2017.05.005]